Mengyu completed her PhD research under the guidance of Dr. Min-Hao Kuo. Her research focuses on small-molecule modulators of the aggregation of hyperphosphorylated tau (p-tau) include potential risk factors and therapeutics for Alzheimer’s disease. Using a combination of in vitro aggregation assay and cell-based cytotoxicity assay, Mengyu has found two prescription drugs as potent p-tau aggregation inhibitors that also attenuate p-tau cytotoxicity. Conversely, selective benzodiazepines were found to enhance p-tau aggregation and cytotoxicity. Mengyu is now working as post-doc with Dr. Kuo on high-throughput screening of p-tau aggregation modulators.